Experts in this interactive, small group discussion present the most up-to-date pipeline for drug development in primary biliary cholangitis (PBC). Speakers address the indications for second-line therapy in PBC; the proposed benefits of various drugs in development and differences in their expected mechanisms of action; and potential management algorithms, considering risks and benefits of each drug. This session provides attendees the opportunity to hold informal conversations with key thought leaders in the field.
Objectives
Describe treatment goals in primary biliary cholangitis (PBC).
Identify candidates for second-line therapies in PBC.
Review the proposed effects of novel therapies in patients with PBC.